CSP
3 min read
15

Osseointegration for Amputees Makes its Education Forum Debut at OTA 2024

October 31, 2024
0

Reading Time: 2 minutes Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA® Implant System to amputees announces its education forum debut. Integrum’s U.S. team recently exhibited at the Orthopedic Trauma Association (OTA) annual meeting, held last week in Montreal.

Continue Reading
CSP
1 min read
16

Change in the number of shares and votes in Sinch AB (publ)

October 31, 2024
0

Reading Time: < 1 minute Stockholm, Sweden – 31 October 2024 – Sinch AB (publ), which is pioneering the way the world communicates through its Customer Communications Cloud, today announces that the number of shares and votes in Sinch AB (publ), registration number 556882-8908 (“Sinch”),

Continue Reading
CSP
2 min read
39

Increase in number of shares and votes in Stendörren

October 31, 2024
0

Reading Time: < 1 minute Press release 31 October 2024 Stendörren Fastigheter AB (publ) (“Stendörren”) announces that Stendörren’s registered number of shares, votes and share capital has increased through the directed share issue of 2,630,208 B shares, corresponding to 2,630,208 votes, which was announced in October 2024.

Continue Reading
CSP
5 min read
132

Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections

October 31, 2024
0

Reading Time: 4 minutes October 31, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the completion of treatment for the first cohort of patients in its proof-of-concept clinical trial for its antifungal drug-candidate BSG005. The cohort

Continue Reading
CSP
3 min read
47

Rule, Build, and Thrive in Tlatoani: Aztec Cities—Out Now in Steam Early Access

October 31, 2024
0

Reading Time: 2 minutes STOCKHOLM, October 31st, 2024 – Today, Paradox Arc, Perspective Games, and Bellwood Studios released their city-building game, Tlatoani: Aztec Cities, into Steam Early Access. The game features a deep simulation of an Aztec city-state along with beautiful hand-drawn 2D graphics that

Continue Reading
CSP
4 min read
41

Sinch Survey Reveals Major Gaps in Email Deliverability Despite 78% Recognizing its Importance

October 31, 2024
0

Reading Time: 3 minutes 53% of Senders Ignore Blocklist Monitoring, and 39% Neglect List Hygiene, Risking Deliverability and Customer Engagement ATLANTA, Georgia, USA and STOCKHOLM, Sweden– October 31, 20204 – Sinch (Sinch AB (publ) – XSTO: SINCH), which is pioneering the way the world communicates

Continue Reading
CSP
1 min read
41

Change in Wetteri Plc’s Management Team

October 31, 2024
0

Reading Time: < 1 minute Wetteri Plc  Stock Exchange Release 31 October 2024 at 16.30 Sanna Räsänen, member of the management team of Wetteri Plc, HR and Communications Director, has resigned from her position. Räsänen will continue to work for Wetteri until 30th November 2024,

Continue Reading
CSP
3 min read
33

Diagonal announces first pilot test at a stud with LAMPlify®

October 31, 2024
0

Reading Time: 2 minutes Read original Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) announces a partnership with Gocksta Stud (Gocksta Stuteri), led by Anne-Sophie Thiam, to conduct a three-month pilot study, which begins immediately. This pilot test will evaluate LAMPlify’s potential for rapid detection

Continue Reading
Spinomenal Celebrates Halloween with Book of the Cursed Release
CSP
2 min read
44

Spinomenal Celebrates Halloween with Book of the Cursed Release

October 31, 2024
0

Reading Time: 2 minutes Leading iGaming content provider Spinomenal is celebrating Halloween with the release of its spine-tingling slot, Book of the Cursed. An eerie soundtrack ensures players will feel goosebumps on the reels which sits within a 5×3 framework. Set within a macabre

Continue Reading
CSP
11 min read
55

Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention

October 31, 2024
0

Reading Time: 8 minutes Vyepti® confirms efficacy in new phase III pivotal SUNRISE trial, meeting primary endpoint with statistically significant reductions in mean monthly migraine days compared with placebo Vyepti® met all key secondary efficacy endpoints in the SUNRISE trial, and the treatment was generally

Continue Reading